Browse the evidence

High-intensity interval training (HIIT) elicits higher plasma lactate concentrations than work-matched moderate-intensity continuous training (MICT) during the exercise bout.

If you do HIIT, you will produce more lactate than if you did moderate continuous training of the same work. This is expected and part of what drives the unique adaptations.

The relationship between fat mass (FM) and fat-free mass (FFM) during weight change is consistent across sex and ethnicity, with a constant (C) of approximately 9.7, indicating that the proportion of weight lost as fat depends primarily on initial FM rather than demographic factors.

Your body's tendency to lose fat versus muscle during weight loss is determined by how much fat you currently have, not by whether you are a man or woman, or by your ethnicity. If you have more fat mass, you will lose a higher proportion of your weight as fat. This rule applies consistently across different demographic groups.

Tirzepatide (5, 10, and 15 mg once weekly) achieves glycaemic targets (HbA1c < 7.0% and ≤ 6.5%) significantly faster than semaglutide 1 mg and insulin degludec in patients with type 2 diabetes.

If you have type 2 diabetes, starting tirzepatide will likely lower your blood sugar (HbA1c) to target levels faster than starting semaglutide 1 mg or insulin degludec, even though you start on a low dose. You will need to wait 4-20 weeks to reach your full maintenance dose depending on the strength chosen, but clinical targets are met sooner with tirzepatide than with the comparators.

Semaglutide demonstrates superior efficacy compared to Liraglutide in reducing hemoglobin A1c (HbA1c) levels, though it shows no significant difference in weight loss or fasting blood sugar (FBS) reduction compared to Liraglutide.

If you are managing Type 2 Diabetes without metformin, switching from Liraglutide to Semaglutide is likely to improve your blood sugar control (HbA1c) more effectively. However, do not expect significantly more weight loss from this switch alone, as both drugs appear to offer similar weight reduction benefits.

Semaglutide demonstrates superior efficacy compared to Dulaglutide in reducing both HbA1c and Fasting Blood Sugar (FBS), but shows no significant difference in weight loss or BMI reduction.

If you are using Dulaglutide and your blood sugar (HbA1c and FBS) is not well-controlled, switching to Semaglutide may offer better glycemic results. However, if your primary goal is weight loss, switching is unlikely to yield additional weight reduction compared to staying on Dulaglutide.

Higher BMI and central obesity are strongly associated with poor glycemic control (HbA1c ≥ 7%) in Japanese adults with Type 2 Diabetes, with over 50% of obese patients failing to meet glycemic targets.

If you have Type 2 Diabetes and are in an obesity class (BMI ≥ 25 kg/m² in Japan), your risk of having high blood sugar (HbA1c ≥ 7%) is over 50%. Managing your body weight is a critical step to improving your glycemic control, especially if you are under 45 years old.

Younger adults (18-44 years) with Type 2 Diabetes and obesity exhibit significantly higher rates of poor glycemic control compared to older adults, despite having higher mean BMI and waist circumference.

If you are under 45 and have Type 2 Diabetes, your blood sugar control is likely worse than older patients with the disease, especially if you carry extra weight around your waist. You need to prioritize weight management and dietary habits more aggressively than older patients to achieve similar glycemic targets.

Liraglutide 3.0 mg administered subcutaneously once daily produces significant but numerically lower weight loss compared to semaglutide and is less cost-effective, though it remains a safe and efficacious option for obesity management.

Liraglutide 3.0mg once daily is an effective treatment for obesity, producing an average 5.6kg weight loss. It is less effective than semaglutide and tirzepatide. It remains a safe option, particularly for those who may not respond as well to other agents or have specific contraindications.

In trained individuals, resistance training to momentary failure produces significant strength increases regardless of repetition duration (from 2s:4s to 30s:30s:30s), provided load and time-under-load are matched.

If you are already trained, you do not need to slow down your reps to get stronger. Whether you lift at a normal speed (2s concentric, 4s eccentric) or extremely slowly (10s or 30s phases), you will gain the same amount of strength as long as you lift a load that makes you fail between 7-10 reps (for normal speed) or 3-5 reps (for slow speed). Focus on reaching failure, not on how fast you move the weight. This allows you to choose a speed that feels best for your joints or schedule.

Resistance training mitigates the diminishing returns of high protein intake (>1.3 g/kg/day) on lean body mass gains.

If you are eating more than 1.3 grams of protein per kilogram of body weight, you should be doing resistance training. Without training, your body becomes less efficient at turning that extra protein into muscle. Training keeps the 'bang for your buck' high even when you eat a lot of protein.

High body mass index (BMI) and obesity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).

Maintaining a healthy body weight is one of the most effective ways to prevent chronic kidney disease. High BMI increases pressure inside the kidney's filtering units (glomeruli) and triggers inflammatory hormones from fat tissue that directly damage kidney structure over time. Even if you do not have diabetes or high blood pressure, excess weight—especially around the waist—increases your risk of kidney failure. Weight management through diet and exercise is a primary preventive strategy for kidney health.

Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, and insulin resistance-induced acidic urine.

If you are overweight, you are at higher risk for kidney stones because your body's metabolism changes how your urine is made. Insulin resistance makes your urine more acidic and increases the amount of stone-forming minerals like oxalate and uric acid you excrete. Managing your weight and insulin sensitivity is key to preventing stones, not just avoiding specific stone-causing foods.

Higher cardiorespiratory fitness (CRF) is independently associated with more favorable left ventricular contractility (lower Ecc), independent of visceral fat levels and other risk factors.

Prioritize improving your cardiorespiratory fitness (VO2max) through structured aerobic exercise, not just general daily movement. Higher fitness protects heart muscle function independently of how much belly fat you have.

Low-carbohydrate diets (20% of energy) increase Total Energy Expenditure (TEE) by approximately 250 kcal/day compared to high-carbohydrate diets (60% of energy) during weight-loss maintenance, supporting the carbohydrate-insulin model.

Adopting a low-carbohydrate diet (around 20% of calories from carbs) may increase your daily energy expenditure by about 250 calories compared to a high-carb diet, even when maintaining the same weight. This metabolic advantage may facilitate long-term weight management.

Dietary protein quality is determined by essential amino acid content and digestibility (DIAAS), with plant proteins generally having lower bioavailability than animal proteins due to antinutrients.

Understand that plant proteins are generally less bioavailable than animal proteins due to antinutrients. To maximize benefit, eat a variety of plant proteins (legumes, grains, nuts) and consider processing methods (heating, fermentation) that improve digestibility. This is especially important for older adults.

Higher estimated glucose disposal rate (eGDR), indicating lower insulin resistance, is independently associated with a reduced risk of incident cardiovascular disease in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3.

For individuals with metabolic risk factors (obesity, high blood pressure, or pre-diabetes), improving insulin sensitivity is a primary strategy for preventing heart disease. While eGDR is a clinical metric, the underlying principle is that reducing insulin resistance—through weight management, physical activity, and dietary quality—lowers cardiovascular risk. This benefit is most pronounced in early stages of metabolic dysfunction (CKM 0-1).

Prolonged sitting is an independent risk factor for Type 2 Diabetes, cardiovascular mortality, and all-cause mortality.

Break up long periods of sitting by standing or moving for a few minutes every 90 minutes to reduce your risk of diabetes and heart disease.

In individuals with Type 2 Diabetes, the 'obesity paradox' exists where the lowest mortality risk is observed in the BMI range of 25–35 kg/m2, but this is largely explained by higher cardiorespiratory fitness (CRF) rather than body weight itself.

Do not fear being overweight if you are fit. In Type 2 Diabetes, the lowest mortality risk is found in those with a BMI of 25-35, but this is because they tend to be more fit. Focus on building fitness. An obese person with high fitness has lower mortality risk than a normal-weight person with low fitness.

Tirzepatide treatment significantly reduces the prevalence of metabolic syndrome in patients with type 2 diabetes compared to placebo, semaglutide, and insulin therapies.

If you have type 2 diabetes, tirzepatide (a once-weekly injection) is highly effective at reducing the cluster of risk factors that make up metabolic syndrome (like high blood sugar, high blood pressure, and high triglycerides). It works better than standard insulin or other common diabetes medications in clinical trials. While lifestyle changes are important, they are often not enough on their own to resolve metabolic syndrome, making this medication a powerful tool for improving your cardiovascular risk profile.

Long-term weight gain (increasing BMI trajectory) in healthy adults significantly increases the risk of incident chronic kidney disease (CKD), with the effect being strongest in overweight and obese individuals.

If you are gaining weight, even if you are currently healthy and have no diagnosed conditions, you are increasing your risk of developing chronic kidney disease. This risk is driven by worsening blood pressure, insulin resistance, and inflammation, as well as increased body fat. Maintaining a stable weight is crucial for kidney health, especially if you are overweight or obese.

Inter-set rest intervals greater than 60 seconds provide a small but detectable hypertrophic benefit for upper and lower limb muscles compared to shorter rest intervals, primarily by preserving volume load.

If your goal is maximum muscle growth, rest 2-3 minutes between sets. While resting less than 60 seconds still works, resting longer allows you to maintain more weight and reps (volume load), leading to slightly better growth, especially in arms and legs. There is no extra benefit to resting longer than 90 seconds.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) significantly reduce hepatic fat content and resolve NASH in patients with NAFLD, primarily through delayed gastric emptying and direct metabolic effects on the liver.

If you have NAFLD or NASH, especially if you are overweight or have type 2 diabetes, GLP-1 receptor agonists like semaglutide (once weekly) and liraglutide are currently the most promising pharmacological treatments for resolving liver fat and NASH. While they can cause temporary gastrointestinal issues like nausea, clinical trials show they significantly improve liver outcomes compared to placebo. Discuss these options with your doctor, as they may offer resolution of steatosis and metabolic improvement.

Incretin receptor agonists (IRAs), including GLP-1RAs and dual GIP/GLP-1RAs, reduce the risk of major adverse cardiovascular events (MACE) and improve lipid profiles and blood pressure in patients with type 2 diabetes.

If you have Type 2 Diabetes and are at risk for heart disease, ask your doctor about GLP-1 receptor agonists (like liraglutide, semaglutide, or dulaglutide). These medications not only help control blood sugar but have been proven in large studies to significantly reduce the risk of heart attacks, strokes, and cardiovascular death. They also help lower blood pressure and improve cholesterol levels. While they are often injectable (with some oral options available), the cardiovascular protection they offer is a major benefit for patients with existing heart conditions.

Statin therapy is safe and effective for cardiovascular risk reduction in patients with MASLD and MASH, and elevated transaminases should not prevent prescription.

If you have fatty liver disease (MASLD/MASH), do not avoid statins due to fear of liver damage. Statins are safe, effective for heart health, and may even improve liver markers. Consult your doctor for appropriate intensity based on your overall cardiovascular risk.